	US 12,134,644 B2
	Anti-IL-17A antibodies and use thereof
Weiqun Shen, Napa, CA (US); Xiangyang Tan, Tewksbury, MA (US); and Jianning Liu, Suzhou (CN)
Appl. No. 17/264,700
Filed by Weiqun Shen, Napa, CA (US); Xiangyang Tan, Tewksbury, MA (US); and Jianning Liu, Suzhou (CN)
PCT Filed Jul. 30, 2019, PCT No. PCT/CN2019/098327 § 371(c)(1), (2) Date Jan. 29, 2021, PCT Pub. No. WO2020/024931, PCT Pub. Date Feb. 6, 2020.
Claims priority of application No. PCT/CN2018/097795 (WO), filed on Jul. 31, 2018.
Prior Publication US 2021/0309735 A1, Oct. 7, 2021
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61P 19/02 (2006.01)

CPC C07K 16/244 (2013.01) [A61P 19/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

14 Claims

1. An antibody or an antigen binding fragment thereof comprising light chain CDR1-3 and heavy chain CDR1-3, wherein the light chain CDR1-3 comprises the amino acid sequence as set forth in SEQ ID NO: 4-6, respectively, and the heavy chain CDR1-3 comprises the amino acid sequence as set forth in SEQ ID NO: 1-3, respectively,

and the antibody or an antigen binding fragment thereof which binds to IL-17A and exhibits at least one of the following properties:

a) binds to IL-17A with a K_Dof 2×10⁻⁹M or less, as measured by bio-layer interferometry;

b) specifically binds to IL-17A, and does not substantially bind to IL-17B, IL-17C, IL-17D, IL-17E, or IL-17F;

c) blocks an interaction between IL-17A and IL-17R;

d) neutralizes IL-17A in vivo;

e) is capable of treating an autoimmune disease or disorder.